Stallion Uranium Announces Flow Through Financing

Stallion Uranium Announces Flow Through Financing GlobeNewswire December 12, 2025 NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) — Stallion Uranium Corp. (the “Company” or “Stallion“) (TSX-V: STUD; OTCQB: STLNF; FSE: B76) is pleased to announce that it is […]

Holiday Grief Intensifies as Americans Seek Practical Relief Methods

Holiday Grief Intensifies as Americans Seek Practical Relief Methods GlobeNewswire December 12, 2025 LOS ANGELES, Dec. 12, 2025 (GLOBE NEWSWIRE) — The first week of December marked National Grief Awareness Week, a time dedicated to recognizing the impact of grief and supporting those who have experienced loss. With the holiday season upon us, these emotions

BioCryst Announces FDA Approval of ORLADEYO(R) (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years

BioCryst Announces FDA Approval of ORLADEYO(R) (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years GlobeNewswire December 12, 2025 –ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older– -Oral pellet formulation provides child-friendly method of administration- -Showed early

Revuforj(R) (revumenib) Named Best New Drug at the Scrip Awards 2025

Revuforj(R) (revumenib) Named Best New Drug at the Scrip Awards 2025 GlobeNewswire December 12, 2025 NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj(R) (revumenib) was named Best New Drug at the Scrip Awards 2025, held by Citeline. The Best

Koryx Copper Announces Further Positive Drill Results at the Haib Copper Project, Southern Namibia

Koryx Copper Announces Further Positive Drill Results at the Haib Copper Project, Southern Namibia GlobeNewswire December 12, 2025 Highlights Assays reported for a further 9 drill holes for 4,007m of diamond drilling. Consistent drill results with excellent localized higher-grade zones providing a potential opportunity for higher-grade mine scheduling within the wider mineral resource envelope. Notable

GXO Appoints Bart Beeks as Chief Operating Officer

GXO Appoints Bart Beeks as Chief Operating Officer GlobeNewswire December 12, 2025 Newly created role responsible for driving global operational excellence GREENWICH, Conn., Dec. 12, 2025 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), the world's largest pure-play contract logistics provider, today announced the appointment of Bart Beeks in the newly created role of Chief

OTC Markets Group Welcomes PensionBee Group plc to OTCQX

OTC Markets Group Welcomes PensionBee Group plc to OTCQX GlobeNewswire December 12, 2025 NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced PensionBee Group plc (LON: PBEE; OTCQX:PBNYF), a leading online retirement savings provider, has qualified to

Nova Leap Health Corp. Grants Stock Options

Nova Leap Health Corp. Grants Stock Options GlobeNewswire December 12, 2025 NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Dec. 12, 2025 (GLOBE NEWSWIRE) — NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a growing home health care organization, announces that the Company

Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025

Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 GlobeNewswire December 12, 2025 Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity

Systematic Review and Meta-Analysis Confirms TissueCypher(R) Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer

Systematic Review and Meta-Analysis Confirms TissueCypher(R) Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer Across multiple published studies, the test consistently identifies high-risk patients whose progression rates exceed guideline-based actionable thresholds for intensified care GlobeNewswire December 12, 2025 FRIENDSWOOD, Texas, Dec. 12, 2025 (GLOBE NEWSWIRE) —

Scroll to Top